Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice
作者： Armin Hekele , Sylvie Bertholet , Jacob Archer , Daniel G Gibson , Giuseppe Palladino
DOI: 10.1038/EMI.2013.54
关键词: Synthetic vaccine 、 Duck embryo vaccine 、 Virus 、 Immunology 、 Virology 、 Hemagglutinin (influenza) 、 Immunization 、 Titer 、 Medicine 、 Neuraminidase 、 Neutralizing antibody
摘要: The timing of vaccine availability is essential for an effective response to pandemic influenza. In 2009, became available after the disease peak, and this has motivated development next generation technologies more rapid responses. SAM(®) platform, now in pre-clinical development, based on a synthetic, self-amplifying mRNA, delivered by synthetic lipid nanoparticle (LNP). When used express seasonal influenza hemagglutinin (HA), SAM elicited potent immune responses, comparable those licensed subunit preparation. sequences coding HA neuraminidase (NA) genes from H7N9 outbreak China were posted web-based data sharing system, combination accurate cell-free gene synthesis technology allowed candidate 8 days. Two weeks first immunization, mice had measurable inhibition (HI) neutralizing antibody titers against new virus. second all HI considered protective. If platform proves safe, potent, well tolerated humans, fully could provide unparalleled speed stem initial wave outbreaks, allowing days discovery
nature.com
sci-hub.se 参考文章(31)
Steve Pascolo, Vaccination with Messenger RNA (mRNA) Handbook of experimental pharmacology. ,vol. 183, pp. 221- 235 ,(2008) , 10.1007/978-3-540-72167-3_11
G F Rimmelzwaan, A C M Boon, A D M E Osterhaus, J C de Jong, W E P Beyer, A M Palache, Haemagglutination-inhibiting antibody to influenza virus. Developments in biologicals. ,vol. 115, pp. 63- 73 ,(2003)
Gabriele Neumann, Yoshihiro Kawaoka, The first influenza pandemic of the new millennium. Influenza and Other Respiratory Viruses. ,vol. 5, pp. 157- 166 ,(2011) , 10.1111/J.1750-2659.2011.00231.X
Steven Black, Uwe Nicolay, Timo Vesikari, Markus Knuf, Giuseppe Del Giudice, Giovanni Della Cioppa, Theodore Tsai, Ralf Clemens, Rino Rappuoli, Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children Pediatric Infectious Disease Journal. ,vol. 30, pp. 1081- 1085 ,(2011) , 10.1097/INF.0B013E3182367662
Jeffrey B. Ulmer, Peter W. Mason, Andrew Geall, Christian W. Mandl, RNA-based vaccines. Vaccine. ,vol. 30, pp. 4414- 4418 ,(2012) , 10.1016/J.VACCINE.2012.04.060
Kathryn L. Jones, Debbie Drane, Eric J. Gowans, Long-term storage of DNA-free RNA for use in vaccine studies BioTechniques. ,vol. 43, pp. 675- 681 ,(2007) , 10.2144/000112593
Michele Tizzoni, Paolo Bajardi, Chiara Poletto, José J Ramasco, Duygu Balcan, Bruno Gonçalves, Nicola Perra, Vittoria Colizza, Alessandro Vespignani, Real-time numerical forecast of global epidemic spreading: case study of 2009 A/H1N1pdm BMC Medicine. ,vol. 10, pp. 165- 165 ,(2012) , 10.1186/1741-7015-10-165
Atika Abelin, Tony Colegate, Stephen Gardner, Norbert Hehme, Abraham Palache, Lessons from pandemic influenza A(H1N1): The research-based vaccine industry's perspective Vaccine. ,vol. 29, pp. 1135- 1138 ,(2011) , 10.1016/J.VACCINE.2010.11.042
Philip Dormitzer, Theodore Tsai, Giuseppe Del Giudice, New technologies for influenza vaccines Human Vaccines & Immunotherapeutics. ,vol. 8, pp. 45- 58 ,(2012) , 10.4161/HV.8.1.18859
Andrew J Geall, Ayush Verma, Gillis R Otten, Christine A Shaw, Armin Hekele, Kaustuv Banerjee, Yen Cu, Clayton W Beard, Luis A Brito, Thomas Krucker, Derek T O’Hagan, Manmohan Singh, Peter W Mason, Nicholas M Valiante, Philip R Dormitzer, Susan W Barnett, Rino Rappuoli, Jeffrey B Ulmer, Christian W Mandl, Nonviral delivery of self-amplifying RNA vaccines Proceedings of the National Academy of Sciences of the United States of America. ,vol. 109, pp. 14604- 14609 ,(2012) , 10.1073/PNAS.1209367109